There are 383 resources available
43P - Update on long term outcome of a multicentre, prospective, real-world study of camrelizumab in the treatment of patients with advanced lung cancer
Presenter: Yongqian Shu
Session: Poster Display session
69P - Tumor invasiveness, response to ALK inhibitors and resistance mechanism in NSCLC with different ALK variants
Presenter: Zihua Zou
Session: Poster Display session
70P - Adherence to treatment recommendations from multidisciplinary tumor boards
Presenter: Julia Roeper
Session: Poster Display session
83P - Pathologic complete response (pCR) after neoadjuvant (neoadj) chemoimmunotherapy (chemo+IO) in resectable non-small cell lung cancer (NSCLC): A systematic review and pooled analysis
Presenter: Samuel Rosner
Session: Poster Display session
72P - The risk factors of developing severity in immune checkpoint inhibitors-related pneumonitis in advanced lung cancer patients
Presenter: Yao Zhang
Session: Poster Display session
73P - A novel nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
Presenter: Sophie cao
Session: Poster Display session
74TiP - Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC/IV EGFR-mutant, T790M-negative, MET-amplified NSCLC
Presenter: Yi-Long Wu
Session: Poster Display session
76TiP - RMC-4630 and sotorasib for advanced KRASG12C NSCLC after failure of prior standard therapies: A phase II trial
Presenter: Melissa Johnson
Session: Poster Display session
93P - Noncancer-specific mortality in patients with stage IA1 NSCLC after surgical resection: The role of comorbidities in prognosis
Presenter: Weijia Huang
Session: Poster Display session